NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
PMV Pharmaceuticals reported financial results for the third quarter of 2021 and provided corporate highlights.
PMV Pharma reported its Q3 2021 financial results, highlighting the progress of its lead candidate, PC14586, and a strong cash position of $326.3 million to support operations through 2023.
- Advanced clinical development of PC14586, a p53 Y220C reactivator.
- Phase 1/2 trial of PC14586 is progressing with twelve sites at leading oncology centers.
- Appointed Tim Smith as Senior Vice President, Head of Corporate Development.
- Cash, cash equivalents, and marketable securities of $326.3 million as of September 30, 2021.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
PMV Pharma expects to present data from the Phase 1/2 trial of PC14586 in the first half of next year and believes its cash position is sufficient to support operations through the end of 2023.
Tailwinds
- Ongoing Phase 1/2 trial of PC14586 progressing well.
- Data from the Phase 1 portion of the trial expected in the first half of 2022.
- Strong cash, cash equivalents and marketable securities position of $326.3 million.
- Cash position sufficient to support execution of clinical, research and operational goals through the end of 2023.
- PC14586 has been granted Fast Track designation by the U.S. FDA.
Headwinds
- The success, cost, and timing of the Company’s product candidate development activities and planned clinical trials
- The Company’s ability to execute on its strategy and operate as an early clinical stage company
- The potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results
- The Company’s ability to fund operations
- The impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro